Tokyo Medical University is a Japanese private university located in Shibuya, Tokyo, Japan. Established in 1916, it is one of the medical schools established in Japan before World War II.

During the past decade, Tokyo Medical University conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 2 clinical trials were completed, i.e. on average, 28.6% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tokyo Medical University" #1 sponsor was "Boston Scientific Corporation" with 2 trials, followed by "Baxalta now part of Shire" with 1 trials sponsored, "Dr. Christoph Schukro" with 1 trials sponsored, "Erasmus Medical Center" with 1 trials sponsored and "Japan Multinational Trial Organization" with 1 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tokyo Medical University" #1 collaborator was "A2 Healthcare Taiwan Corporation" with 1 trials as a collaborator, "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 1 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator, "Boston Scientific Corporation" with 1 trials as a collaborator and "Centro Cardiologico Monzino" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Tokyo Medical University" are "Coronary Artery Disease" (2 trials), "Lung Cancer" (2 trials), "ALS" (1 trials), "Acute Heart Failure" (1 trials) and "Biliary Obstruction Due to Common Bile Duct Stone" (1 trials). Many other conditions were trialed in "Tokyo Medical University" in a lesser frequency.

Most popular intervention types in "Tokyo Medical University" are "Drug" (5 trials), "Procedure" (5 trials), "Device" (3 trials), "Biological" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "BAX 326 (Recombinant factor IX)" (1 trials), "Biliary drainage" (1 trials), "ERCP (Endoscopic Retrograde Cholangiopancreatography)" (1 trials), "Empagliflozin 10 MG" (1 trials) and "Optimal medical therapy (OMT)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Tokyo Medical University" are 15 trials for "All" genders.

Currently, there are NaN active trials in "Tokyo Medical University". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Tokyo Medical University, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Tokyo Medical University, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".

Tokyo Medical University has several departments that took part in Clinical trials: "Tokyo Medical University Hospital; Dept of Surgery" - 3 trials